Extended adjuvant tamoxifen for early breast cancer: a meta-analysis.

ABSTRACT:

Background

Hormone receptor positive breast cancer is characterized by the potential for disease recurrence many years after initial diagnosis. Endocrine therapy has been shown to reduce the risk of such recurrence, but the optimal duration of endocrine therapy remains unclear.

Methods

We conducted a systematic review and meta-analysis to quantify the benefits and harms of extended adjuvant tamoxifen (>5 years of therapy) compared with adjuvant tamoxifen (5 years of therapy). Odds ratios (ORs) and 95% confidence intervals (CIs) were computed for disease recurrence, death and adverse events. Subgroup analyses by timing of recurrence and baseline lymph node and menopause status were carried.

Results

Five trials comprising 21,554 patients were included. Extended adjuvant

SUBMITTER: Al-Mubarak M 

PROVIDER: S-EPMC3930532 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature